182 related articles for article (PubMed ID: 11214425)
1. Elective coronary and valve surgery without blood transfusion in patients treated with recombinant human erythropoietin (epoetin-alpha).
Podestà A; Carmagnini E; Parodi E; Dottori V; Crivellari R; Barberis L; Audo A; Lijoi A; Passerone G
Minerva Cardioangiol; 2000 Nov; 48(11):341-7. PubMed ID: 11214425
[TBL] [Abstract][Full Text] [Related]
2. Epoetin alpha in elective coronary and valve surgery in Jehovah's Witnesses patients. Experience in 45 patients.
Podestà A; Parodi E; Dottori V; Crivellari R; Passerone GC
Minerva Cardioangiol; 2002 Apr; 50(2):125-31. PubMed ID: 12032466
[TBL] [Abstract][Full Text] [Related]
3. The effects of epoetin alfa on transfusion requirements in head and neck cancer patients: a prospective, randomized, placebo-controlled study.
Scott SN; Boeve TJ; McCulloch TM; Fitzpatrick KA; Karnell LH
Laryngoscope; 2002 Jul; 112(7 Pt 1):1221-9. PubMed ID: 12169903
[TBL] [Abstract][Full Text] [Related]
4. Clinical experience with epoetin alfa in the management of hemoglobin levels in orthopedic surgery and cancer. Implications for use in gynecologic surgery.
Stovall TG
J Reprod Med; 2001 May; 46(5 Suppl):531-8. PubMed ID: 11396387
[TBL] [Abstract][Full Text] [Related]
5. Erythropoietin in Jehova's witness heart surgery.
Podestà A; Carmagnini E
Minerva Cardioangiol; 1999; 47(7-8):261-7. PubMed ID: 10582437
[TBL] [Abstract][Full Text] [Related]
6. Preoperative epoetin alfa in colorectal surgery: a randomized, controlled study.
Christodoulakis M; Tsiftsis DD;
Ann Surg Oncol; 2005 Sep; 12(9):718-25. PubMed ID: 16052276
[TBL] [Abstract][Full Text] [Related]
7. [Erythropoietin alone or as an adjuvant for the autologous blood donation program in major orthopedic surgery].
Bisbe E; Sáez M; Nomen N; Castillo J; Santiveri X; Mestre C; Cano X
Rev Esp Anestesiol Reanim; 2003 Oct; 50(8):395-400. PubMed ID: 14601367
[TBL] [Abstract][Full Text] [Related]
8. Epoetin alfa. A bloodless approach for the treatment of perioperative anemia.
Faris PM; Ritter MA
Clin Orthop Relat Res; 1998 Dec; (357):60-7. PubMed ID: 9917701
[TBL] [Abstract][Full Text] [Related]
9. Epoetin alfa as an adjunct to autologous blood donation in patients with a low hematocrit scheduled for elective orthopedic surgery.
Adamson J
Semin Hematol; 1996 Apr; 33(2 Suppl 2):15-6; discussion 17. PubMed ID: 8723575
[TBL] [Abstract][Full Text] [Related]
10. The role of preoperative epoetin alfa in men undergoing radical retropubic prostatectomy.
Rosenblum N; Levine MA; Handler T; Lepor H
J Urol; 2000 Mar; 163(3):829-33. PubMed ID: 10687987
[TBL] [Abstract][Full Text] [Related]
11. Managing anemia and blood loss in elective gynecologic surgery patients.
Rock WA; Meeks GR
J Reprod Med; 2001 May; 46(5 Suppl):507-14. PubMed ID: 11396384
[TBL] [Abstract][Full Text] [Related]
12. Preoperative recombinant human erythropoietin injection versus preoperative autologous blood donation in patients undergoing radical retropubic prostatectomy.
Chun TY; Martin S; Lepor H
Urology; 1997 Nov; 50(5):727-32. PubMed ID: 9372883
[TBL] [Abstract][Full Text] [Related]
13. Epoetin alfa plus autologous blood donation and normovolemic hemodilution in patients scheduled for orthopedic or vascular surgery.
Tryba M
Semin Hematol; 1996 Apr; 33(2 Suppl 2):34-6; discussion 37-8. PubMed ID: 8723580
[TBL] [Abstract][Full Text] [Related]
14. Perioperative epoetin alfa increases red blood cell mass and reduces exposure to transfusions: results of randomized clinical trials.
Goldberg MA
Semin Hematol; 1997 Jul; 34(3 Suppl 2):41-7. PubMed ID: 9253783
[TBL] [Abstract][Full Text] [Related]
15. Subcutaneous epoetin alfa as an adjunct to autologous blood donation before elective coronary artery bypass graft surgery.
Gombotz H
Semin Hematol; 1996 Apr; 33(2 Suppl 2):69-70; discussion 71-2. PubMed ID: 8723587
[TBL] [Abstract][Full Text] [Related]
16. Preoperative epoetin alfa vs autologous blood donation in primary total knee arthroplasty.
Deutsch A; Spaulding J; Marcus RE
J Arthroplasty; 2006 Aug; 21(5):628-35. PubMed ID: 16877146
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa in critically ill patients: results of a randomized, double-blind, placebo-controlled trial.
Vincent JL; Spapen HD; Creteur J; Piagnerelli M; Hubloue I; Diltoer M; Roman A; Stevens E; Vercammen E; Beaver JS
Crit Care Med; 2006 Jun; 34(6):1661-7. PubMed ID: 16607233
[TBL] [Abstract][Full Text] [Related]
19. Erythropoietin, the biology of erythropoiesis and epoetin alfa. An overview.
Bieber E
J Reprod Med; 2001 May; 46(5 Suppl):521-30. PubMed ID: 11396386
[TBL] [Abstract][Full Text] [Related]
20. Prior red blood cell transfusions in cancer patients increase the risk of subsequent transfusions with or without recombinant human erythropoietin management.
Couture F; Turner AR; Melosky B; Xiu L; Plante RK; Lau CY; Quirt I
Oncologist; 2005 Jan; 10(1):63-71. PubMed ID: 15632253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
